TABLE 2.
All-cause Mortality and Cancer incidence Between Two Groups After 1:1 propensity score-matching.
Digoxin group n = 758 | β-blocker group n = 758 | Adjusted hazard ratio (95%CI) | p value | Subdistribution hazard ratio (95%CI) | p value | |
---|---|---|---|---|---|---|
4-year follow-up | ||||||
All-cause mortality | 79 (10.4%) | 37 (4.9%) | 1.74 (1.18–2.59) | 0.006 a | NA | NA |
Cancer incidence | 43 (5.7%) | 30 (4.0%) | 1.26 (0.79–2.02) | 0.34 | 1.99 (1.22–3.01) | 0.006 a |
8-year follow-up | ||||||
All-cause mortality | 103 (13.6%) | 53 (7.0%) | 1.41 (1.01–1.97) | 0.046 a | NA | NA |
Cancer incidence | 57 (7.5%) | 40 (5.3%) | 1.17 (0.78–1.76) | 0.45 | 1.46 (1.01–2.15) | 0.054 |
CCB = calcium channel blocker; CI = confidence interval; Cox proportional hazards regression.
p value < 0.05Subdistribution hazards regression.
p value < 0.05.